Place of triclabendazole in the treatment of human hepatic fascioliasis.

Sporadic outbreaks of Fasciola hepatica have been reported in France, approximately 50 to 100 cases per year The most appropriate therapy remains to be determined. Clinical cases - We report two cases of patients infected with F. hepatica The infection was successfully treated with a single oral dose of triclabendazole (10 mg/kg of body weight). The first patient was a 35-year-old woman presenting pain in the right hypochondria, fever and a slight hypereosinophilia, but with seropositivity for fascioliasis, hepatic nodules on radiological imagery, and F. hepatica eggs in her feces. The second patient was a 23-year-old man who had traveled to Madagascar and stayed there a month before admission. The initial clinical examination was normal, but the biological results showed an important hepatic cytolysis and a positive serology for a diagnosis of hepatic fascioliasis. The clinical tolerance of triclabendazole was excellent for both of these cases and the follow-up state two months after treatment was normal. Comments - According 50 our experience and that recently reported in the literature, triclabendazole may be regarded as the drug of choice for the treatment of human fascioliasis. (C) 1999 Editions scientifiques et medicales Elsevier SAS.